Welcome to Hunterdon Hematology Oncology

Opening Hours : Monday to Friday - 7:30am to 5pm
  Contact : 908-788-6461

An Open-Label, Randomized Phase 3 Trial f Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Study Summary

  • This trial is looking at how various combinations of drugs used to treat multiple myeloma may work in combination with one another
  • Patients will be randomized to one of 3 treatment arms:
    • Control arm: Pomalidomide (oral drug) and dexamethasone (oral drug)
    • Investigational arm: Nivolumab (IV/infusion drug), Pomalidomide (oral drug) and dexamethasone (oral drug)
    • Exploratory arm: Nivolumab (IV drug), Elotuzumab (IV drug), Pomalidomide (oral drug) and dexamethasone (oral drug)
  • Regardless of which treatment arm the patient is assigned, each treatment cycle lasts 28 days
  • For either treatment arm, you will continue the treatment as long as possible. You will only stop taking your treatment if your disease progresses, you become sick from the treatment or you or your physician feel that is it in your best interest to stop the study

Protocol

  • CA209602

Phase

  • III

Investigator

  • Dr. Myron Bednar

Disease

  • Multiple Myeloma

ClickForCTG

Inclusion

  • Must have received ≥2 prior lines of therapy which must have included at least 2 consecutive cycles of an IMID and a proteasome inhibitor alone or in combination
  • Documented refractory or relapsed (R/R) multiple myeloma
  • Must be refractory (progressed on or within 60 days of treatment) to their last treatment
  • Must have measurable disease

NOTE: The inclusion and exclusion criteria for this study may be confusing, so if you are having a hard time deciding if you may be eligible, feel free to contact us!


If you have any questions regarding this study or think that
you or your loved one may be eligible, please feel free to contact:

HHO_ClinicalTrialContact-1HHO_ClinicalTrialContact-2